Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Survival of patients with multiple sclerosis in Denmark : a nationwide, long-term epidemiologic survey. / Brønnum-Hansen, Henrik; Koch-Henriksen, Nils; Hyllested, K.

In: Neurology, Vol. 44, No. 10, 1994, p. 1901-7.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Brønnum-Hansen, H, Koch-Henriksen, N & Hyllested, K 1994, 'Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey', Neurology, vol. 44, no. 10, pp. 1901-7.

APA

Brønnum-Hansen, H., Koch-Henriksen, N., & Hyllested, K. (1994). Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology, 44(10), 1901-7.

Vancouver

Brønnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology. 1994;44(10):1901-7.

Author

Brønnum-Hansen, Henrik ; Koch-Henriksen, Nils ; Hyllested, K. / Survival of patients with multiple sclerosis in Denmark : a nationwide, long-term epidemiologic survey. In: Neurology. 1994 ; Vol. 44, No. 10. pp. 1901-7.

Bibtex

@article{bc483c4acc9142988d1b6ff6a9eb87ad,
title = "Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey",
abstract = "We estimated survival probability and excess death rates for patients with MS on the basis of data from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark (population, five million) since 1948. We reviewed and reclassified all case records according to standardized diagnostic criteria. By linkage to the Danish Central Population Registry, we lost to follow-up only 25 patients who had emigrated. The median survival time from onset of the disease was 28 years in men (compared with 40 years in the matched general male population) and 33 years in women (versus 46 years). The median survival time from diagnosis was 22 years in men (versus 37 years) and 28 years in women (versus 42 years). The excess death rate between onset and follow-up (observed deaths per 1,000 person-years minus the expected number of deaths in a matched general population) was 14.3 in men, which was significantly higher than in women (12.0). Excess mortality increased with age at onset of MS in people of each sex. The 10-year excess death rate has decreased significantly in recent decades. Excess mortality was highest in cases with cerebellar symptoms at onset.",
keywords = "Adult, Age of Onset, Denmark, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Multiple Sclerosis, Proportional Hazards Models, Prospective Studies, Registries, Sex Factors, Survival Analysis, Survival Rate",
author = "Henrik Br{\o}nnum-Hansen and Nils Koch-Henriksen and K Hyllested",
year = "1994",
language = "English",
volume = "44",
pages = "1901--7",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "10",

}

RIS

TY - JOUR

T1 - Survival of patients with multiple sclerosis in Denmark

T2 - a nationwide, long-term epidemiologic survey

AU - Brønnum-Hansen, Henrik

AU - Koch-Henriksen, Nils

AU - Hyllested, K

PY - 1994

Y1 - 1994

N2 - We estimated survival probability and excess death rates for patients with MS on the basis of data from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark (population, five million) since 1948. We reviewed and reclassified all case records according to standardized diagnostic criteria. By linkage to the Danish Central Population Registry, we lost to follow-up only 25 patients who had emigrated. The median survival time from onset of the disease was 28 years in men (compared with 40 years in the matched general male population) and 33 years in women (versus 46 years). The median survival time from diagnosis was 22 years in men (versus 37 years) and 28 years in women (versus 42 years). The excess death rate between onset and follow-up (observed deaths per 1,000 person-years minus the expected number of deaths in a matched general population) was 14.3 in men, which was significantly higher than in women (12.0). Excess mortality increased with age at onset of MS in people of each sex. The 10-year excess death rate has decreased significantly in recent decades. Excess mortality was highest in cases with cerebellar symptoms at onset.

AB - We estimated survival probability and excess death rates for patients with MS on the basis of data from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark (population, five million) since 1948. We reviewed and reclassified all case records according to standardized diagnostic criteria. By linkage to the Danish Central Population Registry, we lost to follow-up only 25 patients who had emigrated. The median survival time from onset of the disease was 28 years in men (compared with 40 years in the matched general male population) and 33 years in women (versus 46 years). The median survival time from diagnosis was 22 years in men (versus 37 years) and 28 years in women (versus 42 years). The excess death rate between onset and follow-up (observed deaths per 1,000 person-years minus the expected number of deaths in a matched general population) was 14.3 in men, which was significantly higher than in women (12.0). Excess mortality increased with age at onset of MS in people of each sex. The 10-year excess death rate has decreased significantly in recent decades. Excess mortality was highest in cases with cerebellar symptoms at onset.

KW - Adult

KW - Age of Onset

KW - Denmark

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis

KW - Proportional Hazards Models

KW - Prospective Studies

KW - Registries

KW - Sex Factors

KW - Survival Analysis

KW - Survival Rate

M3 - Journal article

C2 - 7936244

VL - 44

SP - 1901

EP - 1907

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -

ID: 44174517